Journal articles: 'Suspension nasal spray'

1

MCNAMARA, DAMIAN. "Omnaris Nasal Spray, Allegra Oral Suspension." Pediatric News 40, no. 12 (December 2006): 54. http://dx.doi.org/10.1016/s0031-398x(06)71572-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

MCNAMARA, DAMIAN. "Patanase Nasal Spray, Prilosec Delayed- Release Oral Suspension." Pediatric News 42, no. 5 (May 2008): 31. http://dx.doi.org/10.1016/s0031-398x(08)70230-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chudiwal, Swapnil Sharadkumar, and Mohamed Hassan G. Dehghan. "Quality by design approach for development of suspension nasal spray products: a case study on budesonide nasal suspension." Drug Development and Industrial Pharmacy 42, no. 10 (March 27, 2016): 1643–52. http://dx.doi.org/10.3109/03639045.2016.1160108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Shah, Samir A., Robert L. Berger, John McDermott, Pranav Gupta, David Monteith, Alyson Connor, and Wu Lin. "Regional deposition of mometasone furoate nasal spray suspension in humans." Allergy and Asthma Proceedings 36, no. 1 (January 21, 2015): 48–57. http://dx.doi.org/10.2500/aap.2015.36.3817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mahmud, Khaled, MN Faruque, and KA Faisal. "The Effect of Preoperative Short Course of Oral Steroids followed by Postoperative Topical Nasal Steroids Sprays on Nasal Polyp Recurrence after Endoscopic Nasal Polypectomy." Journal of Dhaka National Medical College & Hospital 17, no. 2 (October 17, 2012): 40–43. http://dx.doi.org/10.3329/jdnmch.v17i2.12215.

Full text

Abstract:

Objective: To evaluate the effect of preoperative short course of oral steroids followed by postoperative topical nasal steroids sprays on nasal polyp recurrence after endoscopic nasal polypectomy. Methods: Forty eight patients of both genders with symptoms and signs of nasal polyps were included in this prospective study between January 2006 and December 2009. Their ages ranged between 18 and 60 years. The sample was divided into two groups. Group I constituted 24 patients treated by endoscopic nasal polypectomy without oral and local steroid therapy. Group II consisted of 24 patients also treated by endoscopic nasal polypectomy but received preoperatively 60mg prednisolone tablets daily for one week and postoperatively topical nasal steroid spray (Mometasone furoate suspension) for three months. All patients were followed up for at least one year. Recurrence of nasal polyps was assessed endoscopically at three, six and 12 months after surgery. Any evidence of nasal polyps-formation of whatever size was considered as recurrence. Results: Forty eight patients (32 males and 16 females) with sinonasal polyposis were included in this study. Male to female ratio was 2:1. Patients age ranged from 18 to 60 years; median age was 42 years. Recurrence rates at three, six and 12 months after surgery for the first group of patients were 8.33% (2 patients), 25% (6 patients) and 41.6% (10 patients) accordingly, while the recurrence rates for the second group were 4.1% (1 patient), 8.3% (2 patients) and 12.5% (3 patients) accordingly. Conclusions: Preoperative short course of oral steroid followed by postoperative nasal steroid spray show significant reduction in the recurrence rate of nasal polyps after endoscopic nasal polypectomy. DOI: http://dx.doi.org/10.3329/jdnmch.v17i2.12215 J. Dhaka National Med. Coll. Hos. 2011; 17 (02): 40-43

APA, Harvard, Vancouver, ISO, and other styles

6

Ricchetti, Alma, Basile N. Landis, Alessandra Maffioli, Roland Giger, Chungkuan Zeng, and Jean-Silvain Lacroix. "Effect of anti-fungal nasal lavage with amphotericin B on nasal polyposis." Journal of Laryngology & Otology 116, no. 4 (April 2002): 261–63. http://dx.doi.org/10.1258/0022215021910708.

Full text

Abstract:

Recent studies have suggested that allergic fungal rhino-sinusitis could be involved in the development of nasal polyposis. The aim of this study was to evaluate the response of anti-fungal nasal lavages. Patients performed nasal lavage with 20 ml of a one per one thousand amphotericin B suspension in each nostril, twice a day, for four weeks. In addition, all patients continued their saline nasal lavage and their conventional topical corticosteroid spray. This study included 74 patients, with a mean age of 46 years (range from 19 to 73). Before anti-fungal treatment, the distribution of nasal polyposis, according to Malm, was: 13 patients in stage I (17.5 per cent), 48 patients in stage II (65 per cent) and 13 patients in stage III (17.5 per cent). After anti-fungal nasal lavages, the total disappearance of nasal polyposis was observed in 29 patients (39 per cent). Eight patients were stage I, 21 stage II, and none stage III. In patients who have had previous endoscopic polypectomy and functional endoscopic sinus surgery, total disappearance of nasal polyposis was seen in 24 patients (47 per cent). Hyper-reactivity to fungal organisms could be one of the mechanisms underlying the development of nasal polyposis. A direct effect of amphotericin B suspension on the integrity of the cell membrane of the polyps’ epithelium could not be excluded.

APA, Harvard, Vancouver, ISO, and other styles

7

Pennington, Justin, Preetanshu Pandey, Henry Tat, Jennifer Willson, and Brent Donovan. "Spray Pattern and Droplet Size Analyses for High-Shear Viscosity Determination of Aqueous Suspension Corticosteroid Nasal Sprays." Drug Development and Industrial Pharmacy 34, no. 9 (January 2008): 923–29. http://dx.doi.org/10.1080/03639040802149046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Day, James, Michael Alexander, Michel Drouin, Charles Frankish, Jorge Mazza, William Moote, Piyush Patel, Helen Ramsdale, and William Yang. "Budesonide Aqueous Nasal Spray and Pressurized Metered Dose Inhaler in the Treatment of Adult Patients with Seasonal Allergic Rhinitis." American Journal of Rhinology 11, no. 1 (January 1997): 77–84. http://dx.doi.org/10.2500/105065897781446847.

Full text

Abstract:

Budesonide, a topical corticosteroid used in the treatment of seasonal allergic rhinitis, can be administered to the nose as an aerosol via a pressurized metered dose inhaler (pMDI) or as a metered nasal pump spray. Studies have shown that about 64% (256 μg) of a nominal dose of 400 μg budesonide pMDI preparation is delivered to the patient compared with 100% of the nominal dose of the pump spray. The present study was undertaken to assess the efficacy and safety of budesonide delivered via a nasal pMDI twice daily (Rhinocort® pMDI, at 400 μg/day) with an aqueous suspension of budesonide delivered via a metered nasal pump spray once daily (Rhinocort® Aqua, at 256 μg/day or 400 μg/day). The multicenter, double-blind, randomized, placebo-controlled, parallel-group study was conducted in 318 patients (154 men, 164 women; aged 12–67 years) with ragweed-induced seasonal allergic rhinitis. A 1-week baseline period was followed by a 3-week treatment. Nasal symptoms were recorded by the patients, adverse events were noted, an overall evaluation of treatment efficacy was made, and urine cortisol and creatinine levels were measured. Substantial or total control of symptoms was achieved in 83.8% of patients treated with 256 μg of aqueous budesonide, 76.3% with 400 μg of aqueous budesonide, and 80.8% with 400 μg of budesonide pMDI; these were all significantly different (p < 0.001) compared with placebo (23.4% of patients). There were no significant differences in the 24-hour urine cortisol levels between the groups and there were few, infrequent adverse events, similar between the groups and resolved completely on discontinuation of treatment. It was concluded that budesonide, given once daily as 256 μg or 400 μg in an aqueous suspension or twice daily as 400 μg in a pMDI provides good alleviation of the symptoms of seasonal allergic rhinitis with no significant risk of suppression of urine cortisol.

APA, Harvard, Vancouver, ISO, and other styles

9

Thomas, Brandon J., Mohammad Absar, Renishkumar Delvadia, Denise S. Conti, Kimberly Witzmann, and Changning Guo. "Analytical method development for characterizing ingredient-specific particle size distributions of nasal spray suspension products." Journal of Pharmaceutical Sciences 110, no. 7 (July 2021): 2778–88. http://dx.doi.org/10.1016/j.xphs.2021.03.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Nakowitsch, Sabine, Christiane Koller, Jan-Marcus Seifert, Marielle König-Schuster, Nicole Unger-Manhart, Cornelia Siegl, Norman Kirchoff, et al. "Saponin Micelles Lead to High Mucosal Permeation and In Vivo Efficacy of Solubilized Budesonide." Pharmaceutics 12, no. 9 (September 5, 2020): 847. http://dx.doi.org/10.3390/pharmaceutics12090847.

Full text

Abstract:

Due to fast nasal mucociliary clearance, only the dissolved drug content can effectively permeate the mucosa and be pharmaceutically active after intranasal application of suspensions. Therefore, the aim of this study was to increase the budesonide concentration in solution of a nasal spray formulation. Budesonide, a highly water-insoluble corticosteroid, was successfully solubilized using a micellar formulation comprising escin, propylene glycol and dexpanthenol in an aqueous buffered environment (“Budesolv”). A formulation based on this micellar system was well-tolerated in the nasal cavity as shown in a good laboratory practice (GLP) local tolerance study in rabbits. Ex vivo permeation studies into porcine nasal mucosa revealed a faster and more efficient absorption. Budesolv with 300 µg/mL solubilized budesonide resulted in a budesonide concentration of 42 µg/g tissue after only 15 min incubation. In comparison, incubation with the marketed product Rhinocort® aqua 64 (1.28 mg/mL budesonide as suspension) led to 15 µg/g tissue. The in vivo tumor-necrosis-factor (TNF)-α secretion in an acute lung inflammation mouse model was significantly reduced (p < 0.001) following a prophylactic treatment with Budesolv compared to Rhinocort® aqua 64. Successful treatment 15 min after the challenge was only possible with Budesolv (40% reduction of TNF-α, p = 0.0012) suggesting a faster onset of action. The data reveal that solubilization based on saponin micelles presents an opportunity for the development of products containing hardly soluble substances that result in a faster onset and a better topical treatment effect.

APA, Harvard, Vancouver, ISO, and other styles

11

Bellussi, Luisa Maria, Desiderio Passali, Emanuela Vesperini, Serena Cocca, Giulio Cesare Passali, Albera Roberto, Pasquale Cassano, et al. "Multicentric study on the efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in respiratory tract infections." Romanian Journal of Rhinology 8, no. 29 (March 1, 2018): 33–37. http://dx.doi.org/10.2478/rjr-2018-0004.

Full text

Abstract:

Abstract BACKGROUND. Bacteriocins are peptides with antimicrobial efficacy produced by certain bacterial species. Probiotics indeed seem a promising method in the prevention of upper respiratory infections and our study would like to contribute to the results available in the literature, in order to underlie their true therapeutic potential role. MATERIAL AND METHODS. Our multicenter pilot prospective study investigates 366 patients from September 2015 to February 2016. All the patients were treated with a topical device made up of a suspension of two specific bacterial strains: Streptococcus salivarius 24SMB and Streptococcus oralis 89a to be administered as nasal spray. The nasal spray was administered twice daily for 7 days per month for three consecutive months. A questionnaire about the subjective efficacy of the therapy correlated to an improvement of symptoms was also collected from patients. RESULTS. After one year from the enrolment, a 70.07% reduction in the number of events compared with the number of expected episodes was observed. CONCLUSION. The aim of our data is to propose a new therapeutic approach to treat the recurrence of upper airway infection and to support an adequate therapy in all cases where the traditional antibiotic therapeutic protocol did not obtain completely efficient results in terms of recurrence.

APA, Harvard, Vancouver, ISO, and other styles

12

Doub, William H., Wallace P. Adams, John A. Spencer, Lucinda F. Buhse, Matthew P. Nelson, and Patrick J. Treado. "Raman Chemical Imaging for Ingredient-specific Particle Size Characterization of Aqueous Suspension Nasal Spray Formulations: A Progress Report." Pharmaceutical Research 24, no. 5 (March 20, 2007): 934–45. http://dx.doi.org/10.1007/s11095-006-9211-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rygg, Alex, Michael Hindle, and P. Worth Longest. "Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics." Journal of Pharmaceutical Sciences 105, no. 6 (June 2016): 1995–2004. http://dx.doi.org/10.1016/j.xphs.2016.03.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rygg, Alex, Michael Hindle, and P. Worth Longest. "Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Effects of Nasal Spray Suspension Particle Size and Properties." Pharmaceutical Research 33, no. 4 (December 21, 2015): 909–21. http://dx.doi.org/10.1007/s11095-015-1837-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Krug, N., J. M. Hohlfeld, H. Geldmacher, M. Larbig, R. Heermann, N. LaVallee, D. T. Nguyen, U. Petzold, and R. Hermann. "Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit." Allergy 60, no. 3 (March 2005): 354–59. http://dx.doi.org/10.1111/j.1398-9995.2005.00703.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Hayden, Frederick G., Ronald B. Turner, Jack M. Gwaltney, Kathy Chi-Burris, Merril Gersten, Poe Hsyu, Amy K. Patick, George J. Smith, and Leora S. Zalman. "Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers." Antimicrobial Agents and Chemotherapy 47, no. 12 (December 2003): 3907–16. http://dx.doi.org/10.1128/aac.47.12.3907-3916.2003.

Full text

Abstract:

ABSTRACT Human rhinovirus (HRV) infections are usually self-limited but may be associated with serious consequences, particularly in those with asthma and chronic respiratory disease. Effective antiviral agents are needed for preventing and treating HRV illnesses. Ruprintrivir (Agouron Pharmaceuticals, Inc., San Diego, Calif.) selectively inhibits HRV 3C protease and shows potent, broad-spectrum anti-HRV activity in vitro. We conducted three double-blind, placebo-controlled clinical trials in 202 healthy volunteers to assess the activity of ruprintrivir in experimental HRV infection. Subjects were randomized to receive intranasal ruprintrivir (8 mg) or placebo sprays as prophylaxis (two or five times daily [2×/day or 5×/day] for 5 days) starting 6 h before infection or as treatment (5×/day for 4 days) starting 24 h after infection. Ruprintrivir prophylaxis reduced the proportion of subjects with positive viral cultures (for 5×/day dosing groups, 44% for ruprintrivir treatment group versus 70% for placebo treatment group [P = 0.03]; for 2×/day dosing groups, 60% for ruprintrivir group versus 92% for placebo group [P = 0.004]) and viral titers but did not decrease the frequency of colds. Ruprintrivir treatment reduced the mean total daily symptom score (2.2 for ruprintrivir treatment group and 3.3 for the placebo treatment group [P = 0.014]) by 33%. Secondary endpoints, including viral titers, individual symptom scores, and nasal discharge weights, were also reduced by ruprintrivir treatment. Overall, ruprintrivir was well tolerated; blood-tinged mucus and nasal passage irritation were the most common adverse effects reported. Pharmacokinetic analysis of plasma and nasal ruprintrivir concentrations revealed intranasal drug residence with minimal systemic absorption. Results from these studies in experimental rhinoviral infection support continued investigation of intranasal ruprintrivir in the setting of natural HRV infection.

APA, Harvard, Vancouver, ISO, and other styles

17

Dokuyucu, Recep, Bulent Gogebakan, and Cengiz Cevik. "Corresponding erdosteine changes autophagy genes expression in hippocampus on Rhinitis medicamentosa model." Genetika 47, no. 3 (2015): 1091–98. http://dx.doi.org/10.2298/gensr1503091d.

Full text

Abstract:

In our study, rats were subjected to Oxymetazoline hydrochloride treatment and Rhinitis medicamentosa (RM) was formed and then autophagy gene expression levels were determined after the application of an antioxidant agent erdosteine (ED). The rats were divided into three groups; Group 1 was the control group. Group 2 (RM) and group 3 (RM+ED) rats received two spray puffs of 0.05% oxymetazoline into the nasal cavities three times daily for eight weeks. After determination of RM in the rats, the RM group were killed. The ED+RM group received 10 mg/kg of an ED suspension. At the end of seven days, these rats were also killed. All groups? hippocampus tissues were obtained for the measurement of autophagy gene expressions. In rhinitis medicamentosa group Atg5, Atg7 and Atg10 gene expressions in the left hippocampus were reduced as compared to control group (p=0.01, p>0.05, p=0.01, respectively). Also, erdosteine treatments were restored mRNA expression of autophagy genes. In right hippocampus of rhinitis medicamentosa group, Atg5 and Atg10 gene expressions was found to be down-regulated as compared to control group (p>0.05, p<0.05, respectively). Both BECN1 and ULK genes expression were found to be reduced in left hippocampus of rhinitis medicamentosa group. Erdosteine applications was restored the expression of these genes (p=0.03, p=0.03, respectively). Additionally, in right hippocampus, Erdosteine application was restored the expression of ULK gene (p=0.01). This is the first report that evaluated the expression autophagy genes in RM rat models and the changes observed after erdosteine applications.

APA, Harvard, Vancouver, ISO, and other styles

18

Sharpe, S. A., V. Sandweiss, J. Tuazon, M. Giordano, L. Witchey-Lakshmanan, J. Hart, and J. Sequeira. "Comparison of the Flow Properties of Aqueous Suspension Corticosteroid Nasal Sprays Under Differing Sampling Conditions." Drug Development and Industrial Pharmacy 29, no. 9 (January 2003): 1005–12. http://dx.doi.org/10.1081/ddc-120025457.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Stern, Martin A., Ronald Dahl, Lars P. Nielsen, Bente Pedersen, and Camilla Schrewelius. "A Comparison of Aqueous Suspensions of Budesonide Nasal Spray (128 μg and 256 μg Once Daily) and Fluticasone Propionate Nasal Spray (200 μg Once Daily) in the Treatment of Adult Patients with Seasonal Allergic Rhinitis." American Journal of Rhinology 11, no. 4 (July 1997): 323–30. http://dx.doi.org/10.2500/105065897781446658.

Full text

Abstract:

The efficacy of aqueous suspensions of budesonide nasal spray and fluticasone propionate nasal spray, in the treatment of seasonal allergic rhinitis, was compared in a large, placebo-controlled, two-center study. A 1-week baseline period was followed by a 4- to 6-week treatment period during which 635 adult patients, aged 18–72 years, were randomized to receive either placebo, budesonide 128 μg, or 256 μg once daily, or fluticasone propionate, 200 μg once daily. Nasal and eye symptoms, overall treatment efficacy and safety assessments were made during the study period. Combined, as well as individual, nasal symptoms were significantly improved in all three active treatment groups compared with placebo therapy. Treatment with 256 μg/day of budesonide was found to be significantly more effective in reducing the sneezing score compared with 200 μg/day of fluticasone propionate. Analysis of symptom scores on days when the pollen count was greater than 10 grains/m3 revealed 256 μg/day of budesonide therapy to be significantly more effective in reducing combined symptom scores as well as the individual scores for sneezing and runny nose, compared with 200 μg/day fluticasone propionate. The higher dose of budesonide (256 μg/day) was also more effective than the lower dose (128 μg/day) in reducing sneezing scores and statistical significance was almost reached for the reduction in combined symptom and runny nose scores. Substantial or total control of symptoms was achieved by 31.4%, 85.3%, 88.4%, and 81.9% of patients receiving placebo, 128 μg/day of budesonide, 256 μg/day of budesonide, and 200 μg/day of fluticasone propionate, respectively. The incidence of adverse events was low in all treatment groups. In conclusion, both budesonide and fluticasone propionate treatments were effective and well-tolerated in the treatment of seasonal allergic rhinitis. However, 256 μg/day of budesonide tended to be more effective than 200 μg/day of fluticasone propionate and 128 μg/day of budesonide, especially when patients were exposed to a higher pollen load.

APA, Harvard, Vancouver, ISO, and other styles

20

ECCLESTON, GILLIAN M., and NICK E. HUDSON. "The Use of a Capillary Rheometer to Determine the Shear and Extensional Flow Behaviour of Nasal Spray Suspensions." Journal of Pharmacy and Pharmacology 52, no. 10 (October 2000): 1223–32. http://dx.doi.org/10.1211/0022357001777351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Farias, Gonçalo, Jagdeep Shur, Robert Price, Elizabeth Bielski, and Bryan Newman. "A Systematic Approach in the Development of the Morphologically-Directed Raman Spectroscopy Methodology for Characterizing Nasal Suspension Drug Products." AAPS Journal 23, no. 4 (May 18, 2021). http://dx.doi.org/10.1208/s12248-021-00605-w.

Full text

Abstract:

AbstractDemonstrating bioequivalence (BE) of nasal suspension sprays is a challenging task. Analytical tools are required to determine the particle size of the active pharmaceutical ingredient (API) and the structure of a relatively complex formulation. This study investigated the utility of the morphologically-directed Raman spectroscopy (MDRS) method to investigate the particle size distribution (PSD) of nasal suspensions. Dissolution was also investigated as an orthogonal technique. Nasal suspension formulations containing different PSD of mometasone furoate monohydrate (MFM) were manufactured. The PSD of the MFM batches was characterized before formulation manufacture using laser diffraction and automated imaging. Upon formulation manufacture, the droplet size, single actuation content, spray pattern, plume geometry, the API dissolution rate, and the API PSD by MDRS were determined. A systematic approach was utilized to develop a robust method for the analysis of the PSD of MFM in Nasonex® and four test formulations containing the MFM API with different particle size specifications. Although the PSD between distinct techniques cannot be directly compared due to inherent differences between these methodologies, the same trend is observed for three out of the four batches. Dissolution analysis confirmed the trend observed by MDRS in terms of PSD. For suspension-based nasal products, MDRS allows the measurement of API PSD which is critical for BE assessment. This approach has been approved for use in lieu of a comparative clinical endpoint BE study [1]. The correlation observed between PSD and dissolution rate extends the use of dissolution as a critical analytical tool demonstrating BE between test and reference products.

APA, Harvard, Vancouver, ISO, and other styles

22

"Regional deposition of mometasone furoate nasal spray suspension in humans." Allergy and Asthma Proceedings, 2014. http://dx.doi.org/10.2500/aap.2015.35.3817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Liu, Qing, Mohammad Absar, Bhawana Saluja, Changning Guo, Badrul Chowdhury, Robert Lionberger, Dale P. Conner, and Bing V. Li. "Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective." AAPS Journal 21, no. 2 (January 7, 2019). http://dx.doi.org/10.1208/s12248-018-0283-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

S, Ramachandran. "NOVEL DRUG DELIVERY SYSTEM THROUGH NASAL (NON-INVASIVE)." Asian Journal of Pharmaceutical and Clinical Research 11 (December 28, 2018). http://dx.doi.org/10.22159/ajpcr.2018.v11s4.31705.

Full text

Abstract:

Intranasal route is the best method for high absorption and direct delivery to the brain. The interests and importance, of this route, are that the systemic effects of drugs when administered through the nasal route, have expanded over recent decades and it used for therapeutic and recreational purposes. In comparison with the parenteral route of drug administration, intra-nasal administration of drugs offers an interesting alternative for achieving systemic therapeutic effects of drugs. The oral administration of the drug produces low drug bioavailability, and this can be minimized using this nasal route. Moreover, the advantage of this route is that it can bypass the first-pass metabolism. Therefore, it is important to understand the potential and limitations of various nasal drug delivery systems. The aim of this review article is to discuss the various pharmaceutical dosage forms that have the potential to be utilized for local or systemic drug administration. It is assumingly expected that this review will help to understand about this route and also to develop suitable intra-nasal formulations to achieve specific therapeutic objectives. The different types of nasal drug formulations that can be used are nasal drops, nasal sprays, nasal gels, nasal suspensions and emulsion, and nasal powders.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Suspension nasal spray'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles